Research programme: virus-like particles - Agilvax

Drug Profile

Research programme: virus-like particles - Agilvax

Alternative Names: AX 03; AX 09; AX 14; Breast cancer immunotherapy - Agilvax; Dengue vaccine - Agilvax; Human papilloma virus vaccine - Agilvax; Malaria vaccine - Agilvax; Non-Hodgkin's lymphoma immunotherapy - Agilvax; Ovarian cancer immunotherapy - Agilvax; Pan-Ebola vaccine - Agilvax; Pan-Filovirus vaccine - Agilvax; Respiratory syncytial virus vaccine - Agilvax

Latest Information Update: 11 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Agilvax
  • Class Virus-like particle vaccines
  • Mechanism of Action CD44 antigen modulators; Immunogenetic stimulants; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Dengue; Human papillomavirus infections; Malaria; Non-Hodgkin's lymphoma; Ovarian cancer; Respiratory syncytial virus infections
  • Research Ebola virus infections; Viral haemorrhagic fevers

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Breast cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 06 Sep 2016 Agilvax receives patent allowance for human papillomavirus vaccine candidate in USA
  • 28 Jul 2016 Agilvax receives SBIR grant from National Institute of Allergy and Infectious Diseases (NIAID) for virus-like particles based vaccine development in Respiratory syncytial virus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top